Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 – A Prospective Observational Study

OBJECTIVE: Spinal muscular atrophy (SMA) is a progressive autosomal recessive motor neuron disease caused by loss of the SMN1 gene. Based on randomized clinical trials in children with SMA type 1 and 2, Nusinersen has been approved as the first treatment for all types of SMA, including adults with S...

Descripción completa

Detalles Bibliográficos
Autores principales: Walter, Maggie C., Wenninger, Stephan, Thiele, Simone, Stauber, Julia, Hiebeler, Miriam, Greckl, Eva, Stahl, Kristina, Pechmann, Astrid, Lochmüller, Hanns, Kirschner, Janbernd, Schoser, Benedikt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918909/
https://www.ncbi.nlm.nih.gov/pubmed/31594243
http://dx.doi.org/10.3233/JND-190416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918909/
https://www.ncbi.nlm.nih.gov/pubmed/31594243
http://dx.doi.org/10.3233/JND-190416

Ejemplares similares